Icatibant Stada Arzneimittel Ag

Icatibant, the active ingredient in Icatibant Stada Arzneimittel Ag, is a bradykinin B2 receptor antagonist presented as an injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with a confirmed diagnosis.

GNH USA supplies Icatibant Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to control swelling associated with hereditary angioedema.

- Hereditary angioedema type I: provides rapid relief of acute swelling episodes. - Hereditary angioedema type II: reduces the duration and severity of attacks. - Hereditary angioedema with normal C1‑inhibitor: alleviates symptoms during acute episodes.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Swelling: transient edema at the site of administration. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or angioedema. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count. - Infection at injection site: cellulitis or abscess formation. - Cardiovascular events: rare chest pain or arrhythmia.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; weigh potential risks to infant. - Renal impairment: use with caution; monitor renal function. - Concomitant ACE inhibitors: increased bradykinin may heighten adverse effects; monitor closely. - Known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may raise bradykinin levels, increasing risk of angioedema. - Angiotensin receptor blockers: similar risk of enhanced bradykinin activity.

Moderate Interactions (Monitor Closely): - NSAIDs: may mask pain, requiring careful assessment. - Estrogen‑containing contraceptives: can affect hereditary angioedema severity. - Other bradykinin antagonists: additive pharmacologic effect may require dose adjustment.